PDF(Pubmed)
Abstract：
UNASSIGNED: Pneumococcal vaccine recommendations have become increasingly complex. This study aims to understand how national immunization technical advisory groups (NITAGs) and health technology assessment (HTA) agencies of 5 European countries and the United States formed their pneumococcal vaccine recommendations, by providing reviewed evidence and key drivers for new recommendations.
UNASSIGNED: Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and National Health Authorities Web sites were screened to capture the evolution of pneumococcal recommendations. A narrative review was conducted on NITAGs and HTA bodies\' Web sites. Assessments of pneumococcal vaccines published from 2009 to 2022 were included.
UNASSIGNED: Thirty-four records were identified including 21 assessments for risk groups, 17 for elderly, and 12 for children. Burden of disease and vaccine characteristics were almost systematically reviewed during assessments. All 6 countries recommended the use of higher-valent pneumococcal vaccine (PCV; i.e., PCV10 and PCV13) in childhood vaccination programs, given their broader serotype coverage and their comparable profile to PCV7. PCV13 was progressively added to the vaccine schedule (in addition to polysaccharide vaccine) in at least the high-risk group, given the high burden in this population and expected additional benefits of PCV13. For the elderly, unlike the United States, European countries issued negative recommendation for PCV13 routine use because of substantial herd effects from childhood vaccination program making PCV13 likely not cost-effective.
UNASSIGNED: This research provides an overview of decision-making processes for higher-valent PCVs recommendations and could be of interest to anticipate the place of next generation of PCVs in the vaccination landscape.
UNASSIGNED: By describing evidence-based criteria for decision making, this study emphasizes the framework analysis of NITAGs and HTA bodies when assessing pneumococcal vaccines and demonstrates that variation exists between countries and also according to population evaluated.While the burden of disease and immunogenicity/efficacy data were almost systematically reviewed by national stakeholders, economic assessments were reported to a lesser extent but played a major role in the limited use of PCV13 in the adult population.
UNASSIGNED: Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and National Health Authorities Web sites were screened to capture the evolution of pneumococcal recommendations. A narrative review was conducted on NITAGs and HTA bodies\' Web sites. Assessments of pneumococcal vaccines published from 2009 to 2022 were included.
UNASSIGNED: Thirty-four records were identified including 21 assessments for risk groups, 17 for elderly, and 12 for children. Burden of disease and vaccine characteristics were almost systematically reviewed during assessments. All 6 countries recommended the use of higher-valent pneumococcal vaccine (PCV; i.e., PCV10 and PCV13) in childhood vaccination programs, given their broader serotype coverage and their comparable profile to PCV7. PCV13 was progressively added to the vaccine schedule (in addition to polysaccharide vaccine) in at least the high-risk group, given the high burden in this population and expected additional benefits of PCV13. For the elderly, unlike the United States, European countries issued negative recommendation for PCV13 routine use because of substantial herd effects from childhood vaccination program making PCV13 likely not cost-effective.
UNASSIGNED: This research provides an overview of decision-making processes for higher-valent PCVs recommendations and could be of interest to anticipate the place of next generation of PCVs in the vaccination landscape.
UNASSIGNED: By describing evidence-based criteria for decision making, this study emphasizes the framework analysis of NITAGs and HTA bodies when assessing pneumococcal vaccines and demonstrates that variation exists between countries and also according to population evaluated.While the burden of disease and immunogenicity/efficacy data were almost systematically reviewed by national stakeholders, economic assessments were reported to a lesser extent but played a major role in the limited use of PCV13 in the adult population.
摘要：
■肺炎球菌疫苗的建议变得越来越复杂。这项研究旨在了解5个欧洲国家和美国的国家免疫技术咨询组（NITAG）和卫生技术评估（HTA）机构如何形成他们的肺炎球菌疫苗建议，通过提供经审查的证据和新建议的关键驱动因素。
■疾病控制和预防中心，欧洲疾病预防和控制中心，和国家卫生当局的网站进行了筛选，以获取肺炎球菌建议的演变。对NITAG和HTA机构网站进行了叙述性审查。包括2009年至2022年发布的肺炎球菌疫苗的评估。
■确定了34条记录，包括21项风险组评估，17老年人12为儿童。在评估过程中，几乎系统地审查了疾病负担和疫苗特征。所有6个国家都建议使用高价肺炎球菌疫苗(PCV；即，PCV10和PCV13）在儿童疫苗接种计划中，考虑到它们更广泛的血清型覆盖率和与PCV7的可比性。至少在高危人群中，PCV13被逐步添加到疫苗时间表中（除了多糖疫苗之外），考虑到这一人群的高负担和PCV13的预期额外益处。对于老年人来说,与美国不同,欧洲国家发布了对PCV13常规使用的负面建议，因为儿童疫苗接种计划的大量羊群效应使PCV13可能不具成本效益。
■本研究概述了更高价PCV建议的决策过程，并可能对预测下一代PCV在疫苗接种领域的地位感兴趣。
■通过描述基于证据的决策标准，这项研究在评估肺炎球菌疫苗时强调了NITAG和HTA机构的框架分析,并表明各国之间以及根据评估的人群存在差异.虽然国家利益攸关方几乎系统地审查了疾病负担和免疫原性/功效数据，据报道,经济评估的程度较小,但在成人人群中PCV13的使用有限方面发挥了重要作用.
■疾病控制和预防中心，欧洲疾病预防和控制中心，和国家卫生当局的网站进行了筛选，以获取肺炎球菌建议的演变。对NITAG和HTA机构网站进行了叙述性审查。包括2009年至2022年发布的肺炎球菌疫苗的评估。
■确定了34条记录，包括21项风险组评估，17老年人12为儿童。在评估过程中，几乎系统地审查了疾病负担和疫苗特征。所有6个国家都建议使用高价肺炎球菌疫苗(PCV；即，PCV10和PCV13）在儿童疫苗接种计划中，考虑到它们更广泛的血清型覆盖率和与PCV7的可比性。至少在高危人群中，PCV13被逐步添加到疫苗时间表中（除了多糖疫苗之外），考虑到这一人群的高负担和PCV13的预期额外益处。对于老年人来说,与美国不同,欧洲国家发布了对PCV13常规使用的负面建议，因为儿童疫苗接种计划的大量羊群效应使PCV13可能不具成本效益。
■本研究概述了更高价PCV建议的决策过程，并可能对预测下一代PCV在疫苗接种领域的地位感兴趣。
■通过描述基于证据的决策标准，这项研究在评估肺炎球菌疫苗时强调了NITAG和HTA机构的框架分析,并表明各国之间以及根据评估的人群存在差异.虽然国家利益攸关方几乎系统地审查了疾病负担和免疫原性/功效数据，据报道,经济评估的程度较小,但在成人人群中PCV13的使用有限方面发挥了重要作用.
